$SIGY News

Sigyn Therapeutics Launches Initiative to Evaluate Emerging Medical Technologies in Former NFL Players at Risk of CTE

CardioDialysisTM, a Next-Generation Technology to Reduce Major Adverse Cardiovascular Events

Scientific American Highlights Scientific Discovery That Supports the Potential Use of CardioDialysis(TM) to Treat Neuroinflammatory Diseases

Sigyn Therapeutics Issues Shareholder Update Regarding Potential Merger and Asset Sale Initiatives

Sigyn Therapeutics Issues Shareholder Update Highlighting the Advancement of CardioDialysis(TM) and New Corporate Initiatives

The Emergence of Blood Purification Devices to Treat Cardiovascular Disease

Sigyn CardioDialysis(TM) Featured on the Big Biz Show

Sigyn Therapeutics Reports Third Quarter Financial Results and Subsequent Introduction of CardioDialysis(TM)

Sigyn Therapeutics Releases Shareholder Letter to Introduce CardioDialysis(TM)

Sigyn Therapeutics, Inc. to Present at the LD Micro Main Event XIX

Sigyn Therapeutics to Present at the Life Sciences Virtual Investor Forum on September 18th

Sigyn Therapeutics Appoints Dr. Christoph Zaba to Its Scientific Advisory Board

Sigyn Therapeutics Announces Cardiovascular Disease Study

RETRANSMISSION: Goldman Small Cap Research Publishes New Research Report on Sigyn Therapeutics Inc.

Goldman Small Cap Research Publishes New Research Report on Sigyn Therapeutics Inc.

Sigyn CEO Note: An Emerging New Industry, 15 Years in the Making

Sigyn CEO Note: Combating the Rising Threat of New Pandemic Viruses

Sigyn Therapeutics to be Featured in Fireside Chat With Zacks Healthcare Analyst

Sigyn Therapeutics to Present at Tomorrow's Emerging Growth Conference

Sigyn Therapeutics to Present at Tomorrow’s Small Cap Growth Virtual Investor Conference